Aliases & Classifications for Kidney Disease

Summaries for Kidney Disease

MedlinePlus : 40 Healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. They also make hormones that keep your bones strong and your blood healthy. But if the kidneys are damaged, they don't work properly. Harmful wastes can build up in your body. Your blood pressure may rise. Your body may retain excess fluid and not make enough red blood cells. This is called kidney failure. If your kidneys fail, you need treatment to replace the work they normally do. The treatment options are dialysis or a kidney transplant. Each treatment has benefits and drawbacks. No matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. But with the help of health care providers, family, and friends, most people with kidney failure can lead full and active lives. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Kidney Disease, also known as kidney diseases, is related to polycystic kidney disease 4 with or without hepatic disease and polycystic kidney disease 5, and has symptoms including polyuria An important gene associated with Kidney Disease is CEP290 (Centrosomal Protein 290). The drugs Heparin and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include the kidney, kidney and heart, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 A urinary system disease that is located in the kidney.

Wikipedia : 72 Kidney disease, also known as nephropathy or renal disease, is damage to or disease of a kidney.... more...

Related Diseases for Kidney Disease

Diseases in the Kidney Disease family:

Acute Kidney Failure Chronic Kidney Failure
Renal Infectious Disease

Diseases related to Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 650)
# Related Disease Score Top Affiliating Genes
1 polycystic kidney disease 4 with or without hepatic disease 34.7 PKD1 PKD2 PKDREJ PKHD1
2 polycystic kidney disease 5 34.6 PKD1 PKD2 PKHD1
3 cystic kidney disease 34.5 CRB2 PKD1 PKD2 PKHD1 UMOD
4 polycystic kidney disease 3 34.4 PKD1 PKD2 PKDREJ
5 polycystic kidney disease 1 34.3 PKD1 PKD1L1 PKD1L2 PKD1L3 PKD2 PKD2L1
6 polycystic kidney disease 2 34.2 PKD1 PKD1L1 PKD1L3 PKD2 PKD2L1 PKD2L2
7 polycystic kidney disease 34.1 PKD1 PKD1L1 PKD1L2 PKD1L3 PKD2 PKD2L1
8 autosomal dominant polycystic kidney disease 33.9 ACE ALB PKD1 PKD2 PKD2L1 PKD2L2
9 end stage renal failure 32.9 ACE ALB COL4A5 CST3 EPO PKD1
10 nephronophthisis 32.8 CEP290 PKD1 PKD2 PKHD1 UMOD
11 chronic kidney failure 32.7 ACE ALB B2M CASR COL4A5 CST3
12 caroli disease 32.5 PKD1 PKHD1
13 polycystic liver disease 1 32.3 PKD1 PKD2 PKHD1
14 alport syndrome, x-linked 32.3 COL4A5 PKDREJ REN
15 polycystic liver disease 32.2 ALB PKD1 PKD2 PKDREJ PKHD1
16 hypokalemia 32.0 ACE CASR REN
17 calciphylaxis 31.6 ALB CASR
18 iga glomerulonephritis 31.5 ACE ALB REN
19 orofaciodigital syndrome i 31.2 CEP290 PKDREJ
20 congenital hepatic fibrosis 31.1 PKD1 PKHD1 REN
21 secondary hyperparathyroidism of renal origin 31.1 ALB CASR EPO
22 arteries, anomalies of 30.6 ACE ALB REN
23 pyelonephritis 30.5 ACE ALB UMOD
24 interstitial nephritis 30.3 ACE ALB REN UMOD
25 uremia 30.3 ALB B2M CASR EPO
26 focal segmental glomerulosclerosis 30.2 ACE ALB COL4A5 CRB2
27 renal hypertension 30.2 ACE ALB EPO REN
28 cerebral aneurysms 30.2 CST3 PKD1
29 renal tuberculosis 30.2 B2M PKDREJ REN
30 hyporeninemic hypoaldosteronism 30.0 ACE REN
31 congestive heart failure 30.0 ACE EPO REN
32 oligohydramnios 29.9 ACE PKHD1 REN
33 acute kidney failure 29.9 ALB B2M CST3 REN
34 hypoaldosteronism 29.8 ACE REN
35 hypertensive retinopathy 29.8 ACE REN
36 urinary tract obstruction 29.6 ALB B2M PKDREJ REN UMOD
37 hypertension, essential 29.6 ACE ALB COL4A5 CST3 PKD1 PKD2
38 urinary system disease 29.2 ACE ALB B2M CST3 EPO PKDREJ
39 epilepsy, progressive myoclonic, 4, with or without renal failure 12.5
40 medullary cystic kidney disease 1 12.4
41 autosomal dominant tubulointerstitial kidney disease, umod-related 12.4
42 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.4
43 autosomal dominant tubulointerstitial kidney disease 12.3
44 autosomal dominant tubulointerstitial kidney disease, muc1-related 12.3
45 medullary cystic kidney disease 2 12.3
46 ventriculomegaly with cystic kidney disease 12.2
47 bifid nose with or without anorectal and renal anomalies 12.2
48 polycystic kidney disease, infantile severe, with tuberous sclerosis 12.1
49 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.1
50 structural heart defects and renal anomalies syndrome 12.1

Comorbidity relations with Kidney Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Alzheimer Disease Aortic Valve Disease 1
Bladder Neck Obstruction Bronchitis
Bronchopneumonia Cardiac Arrest
Cardiogenic Shock Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Diabetic Polyneuropathy
Encephalopathy Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hydronephrosis
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Ischemic Heart Disease
Malignant Essential Hypertension Microvascular Complications of Diabetes 1
Mitral Valve Disease Nephrosclerosis
Paralytic Ileus Peripheral Vascular Disease
Polycystic Kidney Disease Prostate Cancer
Prostatic Hypertrophy Protein-Energy Malnutrition
Pulmonary Hypertension, Primary, 1 Pyelonephritis
Renal Artery Atheroma Renal Artery Disease
Respiratory Failure Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders

Graphical network of the top 20 diseases related to Kidney Disease:



Diseases related to Kidney Disease

Symptoms & Phenotypes for Kidney Disease

UMLS symptoms related to Kidney Disease:


polyuria

MGI Mouse Phenotypes related to Kidney Disease:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 PKD1 PKD2L2 PKD1L1 REN PKD2 EPO
2 cardiovascular system MP:0005385 10.27 PKD2 EPO PKD1 PKHD1 PKD1L1 REN
3 growth/size/body region MP:0005378 10.2 PKD2 PKD1 PKHD1 PKD1L1 UMOD B2M
4 hematopoietic system MP:0005397 10.13 EPO PKD2 PKD1 PKHD1 COL4A5 B2M
5 immune system MP:0005387 10.11 EPO PKD2 PKD1 PKHD1 COL4A5 UMOD
6 mortality/aging MP:0010768 10.1 PKD2 EPO PKD1 PKHD1 PKD1L1 REN
7 digestive/alimentary MP:0005381 10.08 PKD2 PKD1 PKHD1 PKD1L1 B2M CRB2
8 liver/biliary system MP:0005370 9.92 PKD2 EPO PKD1 PKHD1 B2M ACE
9 normal MP:0002873 9.81 EPO PKD2 PKD1 PKHD1 PKD1L1 REN
10 renal/urinary system MP:0005367 9.7 PKD1 PKHD1 PKD1L1 REN PKD2 UMOD
11 reproductive system MP:0005389 9.32 PKDREJ PKD1 PKHD1 PKD1L1 REN PKD1L2

Drugs & Therapeutics for Kidney Disease

Drugs for Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1528)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 46507594 772
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Theophylline Approved Phase 4,Phase 2,Phase 3 58-55-9 2153
4
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4205-90-7 2803
5
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
7
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 122320-73-4 77999
8
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
9
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 111025-46-8 4829
10
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
11
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
12
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
13
Testosterone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 58-22-0 6013
14
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
15
Digoxin Approved Phase 4 20830-75-5 2724385 30322
16
Colchicine Approved Phase 4,Phase 2,Phase 1 64-86-8 2833 6167
17
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
18
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
19
Lopinavir Approved Phase 4,Phase 3,Phase 2 192725-17-0 92727
20
Efavirenz Approved, Investigational Phase 4,Phase 1,Phase 2 154598-52-4 64139
21
Curcumin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 458-37-7 969516
22
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-43-4 5816
23
Nevirapine Approved Phase 4,Phase 1,Phase 2 129618-40-2 4463
24
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
25
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
26
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3 128-13-2 31401
27
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
28
Fluvastatin Approved Phase 4,Phase 3,Phase 2 93957-54-1 1548972
29
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
30
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-31-9 3440
31
Zidovudine Approved Phase 4,Phase 3,Phase 1,Phase 2 30516-87-1 35370
32
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
33
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
34
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
35
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
36
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
37
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 134678-17-4 60825
38
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
39
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 4091 14219
40
Prazosin Approved Phase 4,Phase 3 19216-56-9 4893
41
Nifedipine Approved Phase 4,Phase 3,Phase 2,Phase 1 21829-25-4 4485
42
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 75847-73-3 40466924 5362032
43
Ramipril Approved Phase 4,Phase 3,Phase 2 87333-19-5 5362129
44
Perindopril Approved Phase 4,Phase 3 107133-36-8, 82834-16-0 107807
45
Fosinopril Approved Phase 4,Phase 3,Phase 2 98048-97-6 55891
46
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1 76420-72-9 6917719
47
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 114798-26-4 3961
48
Spironolactone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1952-01-7, 52-01-7 5833
49
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
50
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-93-5 3639

Interventional clinical trials:

(show top 50) (show all 9293)

# Name Status NCT ID Phase Drugs
1 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
2 The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
3 Folic Acid for Prevention of Contrast Induced Nephropathy Unknown status NCT02444013 Phase 4 Folic acid;Placebo
4 The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease Unknown status NCT01165567 Phase 4 sarpogrelate
5 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
6 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
7 Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
8 Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
9 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
10 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4 Oxycodone
11 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
12 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
13 Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
14 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
15 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
16 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
17 N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy Unknown status NCT01491243 Phase 4 Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
18 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
19 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
20 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
21 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
22 Intravenous Iron in Patients With Anemia of Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
23 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy Unknown status NCT02690883 Phase 4 Exenatide;Lispro
24 Aldosterone in Diabetic Nephropathy Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
25 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
26 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
27 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
28 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
29 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Unknown status NCT02648126 Phase 4
30 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
31 Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
32 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
33 COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
34 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
35 Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
36 Effect of Ambulatory BP Monitoring on the CliniCal coUrse and RenAl ouTcomE of CKD Unknown status NCT02417571 Phase 4
37 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
38 Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients Unknown status NCT01198379 Phase 4 aspirin;Placebo
39 Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise Unknown status NCT01481688 Phase 4
40 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
41 Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion Unknown status NCT00443508 Phase 4 adding Certican to therapy;reducing Tacrolimus
42 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4 sirolimus
43 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
44 Aliskiren and Muscle Sympathetic Nerve Activity Unknown status NCT00719316 Phase 4 Aliskiren
45 Far Infrared Therapy on AV Fistula Flow, Endothelial Function and Echocardiography in ESRD Patients Unknown status NCT01138254 Phase 4
46 Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids on Physiological Intestinal Mibrobiota in CKD Unknown status NCT02302287 Phase 4
47 Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy Unknown status NCT01023373 Phase 4 Medical treatment
48 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
49 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
50 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin

Search NIH Clinical Center for Kidney Disease

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: kidney diseases

Genetic Tests for Kidney Disease

Genetic tests related to Kidney Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Kidney 28
2 Nephropathy 28

Anatomical Context for Kidney Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Disease:

18
The Kidney

MalaCards organs/tissues related to Kidney Disease:

38
Kidney, Heart, Bone, Liver, Endothelial, Testes, Lung

Publications for Kidney Disease

Articles related to Kidney Disease:

(show top 50) (show all 4016)
# Title Authors Year
1
Risk Factors for Carotid Artery Disease and Chronic Kidney Disease: Same or Unique? ( 29405657 )
2018
2
Outcome of autosomal dominant polycystic kidney disease patients on peritoneal dialysis: a national retrospective study based on two French registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network). ( 29361078 )
2018
3
Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). ( 29358433 )
2018
4
Pediatric patient with end-stage kidney disease secondary to Eagle-Barrett syndrome and metastatic unresectable hepatoblastoma treated successfully with chemotherapy and liver-kidney transplant. ( 29356335 )
2018
5
Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. ( 29444881 )
2018
6
Urinary orosomucoid is associated with progressive chronic kidney disease stage in patients with sickle cell anemia. ( 29327376 )
2018
7
Diabetic Kidney Disease: Is There a Role for Glycemic Variability? ( 29450720 )
2018
8
3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease. ( 29306987 )
2018
9
Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders. ( 29445837 )
2018
10
The prevalence and association of chronic kidney disease and diabetes in liver cirrhosis using different estimated glomerular filtration rate equation. ( 29416767 )
2018
11
Endovascular treatment of cerebral aneurysm after renal transplantation in polycystic kidney disease. ( 29444616 )
2018
12
Hepcidin and proinflammatory markers inA children with chronic kidney disease: AA case-control studya8c. ( 29451472 )
2018
13
Treatment of Hyperuricemia in Chronic Kidney Disease. ( 29393124 )
2018
14
Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease. ( 29447254 )
2018
15
A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. ( 29439650 )
2018
16
Nutritional therapy in autosomal dominant polycystic kidney disease. ( 29344814 )
2018
17
Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. ( 29447770 )
2018
18
Plasma triglycerides as a risk factor for chronic kidney disease in type 2 diabetes mellitus: Evidence from the northeastern of Thailand. ( 29448006 )
2018
19
Tolvaptan in Later-Stage Polycystic Kidney Disease. ( 29394475 )
2018
20
Volume Reduction in Enlarged Kidneys in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Prior to Renal Transplant with Transcatheter Arterial Embolization (TAE): A Systematic Review and Meta-Analysis. ( 29388019 )
2018
21
EQ-5D-Y for the assessment of health-related quality of life among Taiwanese youth with mild-to-moderate chronic kidney disease. ( 29447362 )
2018
22
A case of unilateral nephrectomy performed for autosomal dominant polycystic kidney disease with marked unilateral enlargement. ( 29388169 )
2018
23
Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan. ( 29423204 )
2018
24
Chronic kidney disease mortality trends in selected Central America countries, 1997-2013: clues to an epidemic of chronic interstitial nephritis of agricultural communities. ( 29437864 )
2018
25
Tolvaptan in Later-Stage Polycystic Kidney Disease. ( 29394474 )
2018
26
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. ( 29306517 )
2018
27
Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease. ( 29420817 )
2018
28
Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). ( 29401581 )
2018
29
Epigenetic Regulation Of Regulatory T Cells In Kidney Disease And Transplantation. ( 29446735 )
2018
30
HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease. ( 29449811 )
2018
31
Aggregation-Induced Emission Probe for Specific Turn-On Quantification of Soluble Transferrin Receptor: An Important Disease Marker for Iron Deficiency Anemia and Kidney Diseases. ( 29271190 )
2018
32
Differential Clinical Outcomes Between Angiographic Complete Versus Incomplete Coronary Revascularization, According to the Presence of Chronic Kidney Disease in the Drug-Eluting Stent Era. ( 29449272 )
2018
33
Evaluation of Serum Symmetric Dimethylarginine Concentration as a Marker for Masked Chronic Kidney Disease in Cats With Hyperthyroidism. ( 29377360 )
2018
34
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( 29393109 )
2018
35
Tolvaptan in Later-Stage Polycystic Kidney Disease. ( 29385372 )
2018
36
Long-term prognosis after childhood kidney disease. ( 29449211 )
2018
37
Recommendations for Diagnostic and Prognostic Evaluation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) with a Focus on Imaging. ( 29382260 )
2018
38
The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. ( 29338003 )
2018
39
Outcomes of renal transplant from donors with polycystic kidney disease. ( 29425828 )
2018
40
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. ( 29430193 )
2018
41
Relation of uric acid level to rapid kidney function decline and development of kidney disease: The Jackson Heart Study. ( 29450959 )
2018
42
Hepatopleural Fistula with Empyema Thoracis: A Rare Complication of Autosomal Dominant Polycystic Kidney Disease. ( 29379816 )
2018
43
Role of Immune Cells in Diabetic Kidney Disease. ( 29446740 )
2018
44
Ectopic Phosphorylated Creb Marks Dedifferentiated Proximal Tubules in Cystic Kidney Disease. ( 29107072 )
2018
45
Proton Pump Inhibitors and Chronic Kidney Disease: Is It Related to the Accumulation of Toxic Breakdown Products Spontaneously Formed in the Enteric-Protected Tablets? ( 29452088 )
2018
46
Chronic kidney disease and acquired mitochondrial myopathy. ( 29266014 )
2018
47
Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. ( 29449603 )
2018
48
Influence of concurrent chronic kidney disease on intraoperative parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism. ( 29128188 )
2018
49
Cardiac Magnetic Resonance Imaging of the Myocardium in Chronic Kidney Disease. ( 29444516 )
2018
50
REPRISE: tolvaptan in advanced polycystic kidney disease. ( 29389391 )
2018